- Home
- MERC vs MCRB Comparison
MERC vs MCRB Comparison
Compare MERC & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MERC | MCRB |
|---|---|---|
| Founded | 1968 | 2010 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Paper | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 60.2M | 71.0M |
| IPO Year | 2005 | 2015 |
Fundamental Metrics
Financial Performance| Metric | MERC | MCRB |
|---|---|---|
| Price | $0.73 | $6.99 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 2 |
| Target Price | $2.25 | ★ $14.00 |
| AVG Volume (30 Days) | ★ 384.5K | 80.1K |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | ★ 7.01% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,169,145,000.00 | $789,000.00 |
| Revenue This Year | $13.75 | N/A |
| Revenue Next Year | $10.12 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 25.50 | N/A |
| 52 Week Low | $0.71 | $5.31 |
| 52 Week High | $4.47 | $29.98 |
Technical Indicators
Market Signals| Indicator | MERC | MCRB |
|---|---|---|
| Relative Strength Index (RSI) | 34.23 | 51.21 |
| Support Level | N/A | $6.56 |
| Resistance Level | $1.06 | $9.53 |
| Average True Range (ATR) | 0.08 | 0.75 |
| MACD | -0.01 | 0.11 |
| Stochastic Oscillator | 8.90 | 67.67 |
Price Performance
Historical ComparisonAbout MERC Mercer International Inc.
Mercer International Inc is a forest products company with two reportable operating segments in pulp and solid wood. The pulp segment consists of the manufacture, sale, and distribution of pulp, electricity, and chemicals. The company has a geographical presence in the USA, Germany, China, and Other countries, where the maximum of revenue is generated from the China. The majority of the revenue is generated from the Pulp segment.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. The company operates as a single reportable segment, mainly developing microbiome-based therapies targeting bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases.